NASDAQ:ORGO

Organogenesis Competitors

$21.46
-1.14 (-5.04 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$20.87
Now: $21.46
$23.34
50-Day Range
$14.51
MA: $18.29
$22.98
52-Week Range
$2.86
Now: $21.46
$24.34
Volume598,795 shs
Average Volume878,984 shs
Market Capitalization$2.75 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.84

Competitors

Organogenesis (NASDAQ:ORGO) Vs. RDY, BHC, JAZZ, MRVI, UTHR, and BBIO

Should you be buying ORGO stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Organogenesis, including Dr. Reddy's Laboratories (RDY), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), Maravai LifeSciences (MRVI), United Therapeutics (UTHR), and BridgeBio Pharma (BBIO).

Dr. Reddy's Laboratories (NYSE:RDY) and Organogenesis (NASDAQ:ORGO) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, analyst recommendations, profitability and institutional ownership.

Insider and Institutional Ownership

12.9% of Dr. Reddy's Laboratories shares are held by institutional investors. Comparatively, 4.6% of Organogenesis shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Comparatively, 57.2% of Organogenesis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Dr. Reddy's Laboratories and Organogenesis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Dr. Reddy's Laboratories8.23%16.33%10.79%
Organogenesis-1.61%-10.03%-2.22%

Risk and Volatility

Dr. Reddy's Laboratories has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500. Comparatively, Organogenesis has a beta of 1.84, indicating that its stock price is 84% more volatile than the S&P 500.

Valuation & Earnings

This table compares Dr. Reddy's Laboratories and Organogenesis' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dr. Reddy's Laboratories$2.32 billion4.67$259 million$2.7923.30
Organogenesis$260.98 million10.52$-40,450,000.00($0.42)-51.10

Dr. Reddy's Laboratories has higher revenue and earnings than Organogenesis. Organogenesis is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Dr. Reddy's Laboratories and Organogenesis, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Dr. Reddy's Laboratories00403.00
Organogenesis00403.00

Dr. Reddy's Laboratories currently has a consensus target price of $70.00, indicating a potential upside of 7.68%. Organogenesis has a consensus target price of $16.50, indicating a potential downside of 23.11%. Given Dr. Reddy's Laboratories' higher probable upside, equities analysts plainly believe Dr. Reddy's Laboratories is more favorable than Organogenesis.

Summary

Dr. Reddy's Laboratories beats Organogenesis on 9 of the 12 factors compared between the two stocks.

Bausch Health Companies (NYSE:BHC) and Organogenesis (NASDAQ:ORGO) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, profitability, analyst recommendations, institutional ownership and valuation.

Insider & Institutional Ownership

62.9% of Bausch Health Companies shares are held by institutional investors. Comparatively, 4.6% of Organogenesis shares are held by institutional investors. 12.1% of Bausch Health Companies shares are held by company insiders. Comparatively, 57.2% of Organogenesis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Bausch Health Companies and Organogenesis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bausch Health Companies-23.92%173.20%4.21%
Organogenesis-1.61%-10.03%-2.22%

Risk and Volatility

Bausch Health Companies has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500. Comparatively, Organogenesis has a beta of 1.84, meaning that its share price is 84% more volatile than the S&P 500.

Earnings and Valuation

This table compares Bausch Health Companies and Organogenesis' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bausch Health Companies$8.60 billion1.24$-1,788,000,000.00$4.436.77
Organogenesis$260.98 million10.52$-40,450,000.00($0.42)-51.10

Organogenesis has lower revenue, but higher earnings than Bausch Health Companies. Organogenesis is trading at a lower price-to-earnings ratio than Bausch Health Companies, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Bausch Health Companies and Organogenesis, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bausch Health Companies14702.50
Organogenesis00403.00

Bausch Health Companies presently has a consensus target price of $32.5833, indicating a potential upside of 8.68%. Organogenesis has a consensus target price of $16.50, indicating a potential downside of 23.11%. Given Bausch Health Companies' higher probable upside, equities research analysts plainly believe Bausch Health Companies is more favorable than Organogenesis.

Summary

Bausch Health Companies beats Organogenesis on 8 of the 14 factors compared between the two stocks.

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Organogenesis (NASDAQ:ORGO) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, profitability, analyst recommendations, institutional ownership and valuation.

Insider & Institutional Ownership

95.7% of Jazz Pharmaceuticals shares are held by institutional investors. Comparatively, 4.6% of Organogenesis shares are held by institutional investors. 4.6% of Jazz Pharmaceuticals shares are held by company insiders. Comparatively, 57.2% of Organogenesis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Jazz Pharmaceuticals and Organogenesis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Jazz Pharmaceuticals7.86%20.16%10.85%
Organogenesis-1.61%-10.03%-2.22%

Risk and Volatility

Jazz Pharmaceuticals has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Comparatively, Organogenesis has a beta of 1.84, meaning that its share price is 84% more volatile than the S&P 500.

Earnings and Valuation

This table compares Jazz Pharmaceuticals and Organogenesis' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jazz Pharmaceuticals$2.16 billion4.41$523.37 million$14.6011.58
Organogenesis$260.98 million10.52$-40,450,000.00($0.42)-51.10

Jazz Pharmaceuticals has higher revenue and earnings than Organogenesis. Organogenesis is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Jazz Pharmaceuticals and Organogenesis, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Jazz Pharmaceuticals111602.83
Organogenesis00403.00

Jazz Pharmaceuticals presently has a consensus target price of $186.7778, indicating a potential upside of 10.44%. Organogenesis has a consensus target price of $16.50, indicating a potential downside of 23.11%. Given Jazz Pharmaceuticals' higher probable upside, equities research analysts plainly believe Jazz Pharmaceuticals is more favorable than Organogenesis.

Summary

Jazz Pharmaceuticals beats Organogenesis on 10 of the 14 factors compared between the two stocks.

Maravai LifeSciences (NASDAQ:MRVI) and Organogenesis (NASDAQ:ORGO) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, profitability, analyst recommendations, institutional ownership and valuation.

Insider & Institutional Ownership

4.6% of Organogenesis shares are held by institutional investors. 57.2% of Organogenesis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Maravai LifeSciences and Organogenesis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Maravai LifeSciencesN/AN/AN/A
Organogenesis-1.61%-10.03%-2.22%

Earnings and Valuation

This table compares Maravai LifeSciences and Organogenesis' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Maravai LifeSciencesN/AN/AN/AN/AN/A
Organogenesis$260.98 million10.52$-40,450,000.00($0.42)-51.10

Maravai LifeSciences has higher earnings, but lower revenue than Organogenesis.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Maravai LifeSciences and Organogenesis, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Maravai LifeSciences001003.00
Organogenesis00403.00

Maravai LifeSciences presently has a consensus target price of $38.1250, indicating a potential upside of 3.94%. Organogenesis has a consensus target price of $16.50, indicating a potential downside of 23.11%. Given Maravai LifeSciences' higher probable upside, equities research analysts plainly believe Maravai LifeSciences is more favorable than Organogenesis.

Summary

Maravai LifeSciences beats Organogenesis on 5 of the 8 factors compared between the two stocks.

United Therapeutics (NASDAQ:UTHR) and Organogenesis (NASDAQ:ORGO) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, profitability, analyst recommendations, institutional ownership and valuation.

Earnings and Valuation

This table compares United Therapeutics and Organogenesis' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
United Therapeutics$1.45 billion6.27$-104,500,000.00($2.39)-85.29
Organogenesis$260.98 million10.52$-40,450,000.00($0.42)-51.10

Organogenesis has lower revenue, but higher earnings than United Therapeutics. United Therapeutics is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares United Therapeutics and Organogenesis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
United Therapeutics33.25%15.48%11.31%
Organogenesis-1.61%-10.03%-2.22%

Insider & Institutional Ownership

90.1% of United Therapeutics shares are held by institutional investors. Comparatively, 4.6% of Organogenesis shares are held by institutional investors. 10.9% of United Therapeutics shares are held by company insiders. Comparatively, 57.2% of Organogenesis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for United Therapeutics and Organogenesis, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
United Therapeutics00703.00
Organogenesis00403.00

United Therapeutics presently has a consensus target price of $219.5714, indicating a potential upside of 7.71%. Organogenesis has a consensus target price of $16.50, indicating a potential downside of 23.11%. Given United Therapeutics' higher probable upside, equities research analysts plainly believe United Therapeutics is more favorable than Organogenesis.

Risk and Volatility

United Therapeutics has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500. Comparatively, Organogenesis has a beta of 1.84, meaning that its share price is 84% more volatile than the S&P 500.

Summary

United Therapeutics beats Organogenesis on 8 of the 13 factors compared between the two stocks.

Organogenesis (NASDAQ:ORGO) and BridgeBio Pharma (NASDAQ:BBIO) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, profitability and dividends.

Valuation & Earnings

This table compares Organogenesis and BridgeBio Pharma's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Organogenesis$260.98 million10.52$-40,450,000.00($0.42)-51.10
BridgeBio Pharma$40.56 million201.80$-260,590,000.00($2.48)-22.16

Organogenesis has higher revenue and earnings than BridgeBio Pharma. Organogenesis is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Organogenesis and BridgeBio Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Organogenesis-1.61%-10.03%-2.22%
BridgeBio PharmaN/A-109.88%-48.54%

Insider & Institutional Ownership

4.6% of Organogenesis shares are held by institutional investors. Comparatively, 95.5% of BridgeBio Pharma shares are held by institutional investors. 57.2% of Organogenesis shares are held by insiders. Comparatively, 40.3% of BridgeBio Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations for Organogenesis and BridgeBio Pharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Organogenesis00403.00
BridgeBio Pharma01902.90

Organogenesis presently has a consensus price target of $16.50, indicating a potential downside of 23.11%. BridgeBio Pharma has a consensus price target of $72.8889, indicating a potential upside of 32.65%. Given BridgeBio Pharma's higher probable upside, analysts clearly believe BridgeBio Pharma is more favorable than Organogenesis.

Volatility & Risk

Organogenesis has a beta of 1.84, suggesting that its share price is 84% more volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500.

Summary

Organogenesis beats BridgeBio Pharma on 8 of the 14 factors compared between the two stocks.


Organogenesis Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.3$65.01-1.4%$10.81 billion$2.32 billion53.73
Bausch Health Companies logo
BHC
Bausch Health Companies
1.7$29.98-1.1%$10.78 billion$8.60 billion-5.50
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$169.12-0.4%$9.48 billion$2.16 billion53.35Analyst Report
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.6$36.68-0.1%$9.45 billionN/A0.00Increase in Short Interest
United Therapeutics logo
UTHR
United Therapeutics
1.5$203.85-1.1%$8.98 billion$1.45 billion19.29Analyst Report
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0$54.95-1.5%$8.19 billion$40.56 million-16.11
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$158.19-3.7%$8.01 billion$3.34 million-20.54News Coverage
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.4$108.72-0.8%$7.28 billion$103.71 million-24.77Analyst Revision
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$67.65-0.5%$7.02 billion$87.99 million-80.54
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$218.90-0.0%$6.86 billion$311.33 million-127.27Increase in Short Interest
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$121.95-1.8%$6.55 billion$14.98 million-14.85Analyst Downgrade
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$44.78-2.3%$6.30 billion$150,000.00-21.12Unusual Options Activity
News Coverage
Gap Down
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$40.78-0.6%$5.74 billion$1.12 billion84.96
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$71.80-1.2%$5.70 billion$380.83 million-9.18Analyst Report
Perrigo logo
PRGO
Perrigo
2.3$41.62-1.1%$5.56 billion$4.84 billion-693.55
Allakos logo
ALLK
Allakos
1.7$104.50-3.5%$5.55 billionN/A-38.14Insider Selling
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$95.20-0.8%$5.52 billion$66.51 million17.56Analyst Report
Analyst Revision
Schrödinger logo
SDGR
Schrödinger
1.3$78.18-0.2%$5.49 billion$85.54 million0.00Insider Selling
News Coverage
Galapagos logo
GLPG
Galapagos
1.3$79.15-0.3%$5.19 billion$1.00 billion-11.99Analyst Upgrade
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$74.40-1.9%$4.62 billionN/A-6.06Analyst Revision
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$76.13-0.8%$4.41 billion$6.87 million-7.36Unusual Options Activity
Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.25-0.4%$4.26 billion$204.89 million-36.56
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$77.64-4.1%$4.16 billion$1.11 billion24.96Analyst Report
I-Mab logo
IMAB
I-Mab
1.2$57.00-0.2%$4.10 billion$4.31 million-1.97Increase in Short Interest
Gap Up
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$65.90-3.2%$3.98 billion$806.43 million-9.33Analyst Report
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$54.69-0.6%$3.82 billion$117.91 million-11.09
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$44.94-2.4%$3.72 billionN/A0.00Analyst Report
Increase in Short Interest
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$45.57-1.8%$3.66 billionN/A-6.14Analyst Report
Analyst Revision
News Coverage
Gap Down
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$73.03-5.8%$3.58 billionN/A-20.81Analyst Report
Insmed logo
INSM
Insmed
1.2$32.62-3.1%$3.47 billion$136.47 million-12.55
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.00-1.9%$3.46 billion$114.62 million-7.66Analyst Report
LEGN
Legend Biotech
1.2$26.00-0.8%$3.46 billion$64.39 million0.00Decrease in Short Interest
Gap Down
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.14-0.3%$3.39 billion$339.08 million-12.29Analyst Report
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$48.96-1.6%$3.39 billion$306.98 million-7.00
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$90.87-1.5%$3.29 billion$26.52 million-8.01
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$46.54-1.3%$3.25 billion$36.13 million-69.46
Alkermes logo
ALKS
Alkermes
1.2$19.87-0.5%$3.16 billion$1.17 billion-43.19
Arvinas logo
ARVN
Arvinas
1.5$64.69-2.6%$3.16 billion$42.98 million-25.27
MorphoSys logo
MOR
MorphoSys
0.3$22.75-1.9%$3.05 billion$80.43 million108.34Decrease in Short Interest
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$112.60-4.2%$3.04 billionN/A-56.02Insider Selling
OPKO Health logo
OPK
OPKO Health
1.9$4.34-0.5%$2.91 billion$901.90 million-24.11
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
0.9$75.64-1.6%$2.89 billion$644.77 million-10.79
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.1$63.07-5.2%$2.77 billion$421.03 million22.21Analyst Report
Insider Selling
News Coverage
Gap Up
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$47.00-0.5%$2.71 billion$25 million-9.40Insider Selling
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$43.67-0.3%$2.71 billionN/A-23.99
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.77-0.7%$2.67 billion$306.49 million25.58
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.94-3.9%$2.63 billion$182.24 million-8.64Analyst Upgrade
Xencor logo
XNCR
Xencor
1.2$42.78-4.4%$2.59 billion$156.70 million-30.56
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.81-1.3%$2.54 billion$2.11 million-8.83Analyst Report
Analyst Revision
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.22-3.6%$2.53 billion$60,000.00-9.70
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.